Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young.
Thomas J Oxley,J Mocco,Shahram Majidi,Christopher P. Kellner,Hazem Shoirah,I. Paul Singh,Reade De Leacy,Tomoyoshi Shigematsu,Travis R. Ladner,Kurt A. Yaeger,Maryna Skliut,Jesse Weinberger,Neha S. Dangayach,Joshua B. Bederson,Stanley Tuhrim,Johanna T Fifi +15 more
Reads0
Chats0
TLDR
Five patients younger than 50 years of age with large-vessel stroke and Covid-19 infection presented to a health system in New York City over a 2-week period with signs of stroke and infection.Abstract:
Stroke in Young Patients with Covid-19 Five patients younger than 50 years of age with large-vessel stroke and Covid-19 infection presented to a health system in New York City over a 2-week period....read more
Citations
More filters
Journal ArticleDOI
The Epidemiological and Mechanistic Understanding of the Neurological Manifestations of COVID-19: A Comprehensive Meta-Analysis and a Network Medicine Observation.
Jiayu Shen,Yuan Hou,Yadi Zhou,Reena Mehra,Lara Jehi,Lara Jehi,Feixiong Cheng,Feixiong Cheng,Feixiong Cheng +8 more
TL;DR: An elevated vulnerability of those with a history of stroke to severe COVID-19 underlying inflammatory responses (i e , VCAM-1 and procoagulant pathways) is identified, suggesting monotonic relationships, thus implicating causality.
Journal ArticleDOI
Symptoms of Pleurisy as the Initial Presentation of COVID-19.
TL;DR: A 48-year-old man with hypertension and type 2 diabetes mellitus presented to the Emergency Department with acute-onset pleuritic chest pain that was the initial manifestation of COVID-19 which, to the best of my knowledge, has not yet been reported in the literature.
Journal ArticleDOI
SARS-CoV-2 and the Eye: The Pandora's Box of Ocular Immunology.
TL;DR: Wang et al. as mentioned in this paper reviewed the literature and elaborated the available data to speculate on possible new interpretation of both pathophysiology and treatment of SARS-CoV-2.
Journal ArticleDOI
[Clinical and pathogenetic aspects of nervous system impairments in COVID-19]
TL;DR: The most common type is a secondary impairment of the nervous system presented with encephalopathy of hypoxic, infectious/toxic or dysmetabolic origin and its major mechanism is related to the brain edema while clinical presentations include non-specific symptoms such as headaches, dizziness and consciousness impairments.
Journal ArticleDOI
Neurology and the COVID-19 Pandemic: Gathering Data for an Informed Response
TL;DR: Evidence and data regarding neurologic sequelae of COVID-19 and the neuroinvasive potential of human coronaviruses are provided along with a summary of patient registries of interest to the Neurology community.
References
More filters
Journal ArticleDOI
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Fei Zhou,Ting Yu,Ronghui Du,Guohui Fan,Ying Liu,Zhibo Liu,Jie Xiang,Yeming Wang,Bin Song,Xiaoying Gu,Xiaoying Gu,Lulu Guan,Yuan Wei,Li Hui,Xudong Wu,Jiuyang Xu,Shengjin Tu,Yi Zhang,Hua Chen,Bin Cao +19 more
TL;DR: Wang et al. as discussed by the authors used univariable and multivariable logistic regression methods to explore the risk factors associated with in-hospital death, including older age, high SOFA score and d-dimer greater than 1 μg/mL.
Journal ArticleDOI
Large artery ischaemic stroke in severe acute respiratory syndrome (SARS).
T. Umapathi,Ai Ching Kor,Narayanaswamy Venketasubramanian,C. C. Tchoyoson Lim,Boon Chuan Pang,Tseng Tsai Yeo,Cheng Chuan Lee,Poh Lian Lim,Poh Lian Lim,Kuperan Ponnudurai,Khoon Leong Chuah,Puay Hoon Tan,Dessmon Y.H. Tai,Sze Peng Brenda Ang +13 more
TL;DR: It is believed that increased vigilance against stroke and other thrombotic complications among critically-ill SARS patients in future outbreaks is needed, especially if treatment such as intravenous immunoglobulin, that increases pro-thrombosis tendency, is contemplated.
Journal ArticleDOI
Erythropoietin as candidate for supportive treatment of severe COVID-19.
Hannelore Ehrenreich,Karin Weissenborn,Martin Begemann,Martin Begemann,Markus Busch,Eduard Vieta,Kamilla W. Miskowiak +6 more
TL;DR: Evidence that supports the use of human recombinant erythropoietin (EPO) for ameliorating course and outcome of seriously ill COVID-19 patients is recap here and the research design for a double-blind placebo-controlled randomized clinical trial including severely affected patients is planned to start shortly.
Journal ArticleDOI
Revisiting the Protein C Pathway: An Opportunity for Adjunctive Intervention in COVID-19?
TL;DR: The objective of this study was to establish a baseline for the evaluation of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis.
Journal ArticleDOI
COVID-19-associated pulmonary and cerebral thromboembolic disease
TL;DR: A case of a 79-year-old woman that presented with stroke and was found to have COVID-19 pneumonia and concomitant large burden pulmonary arterial clot is reported.
Related Papers (5)
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more